Matylda K.
- Country
- Poland
- Department
- N/A
Research Overview
- Open-Label Rollover Study of AMG 732 in Thyroid Eye Disease Nonresponders and Relapsed Participants
- Evaluation of AMG 732 Efficacy and Safety in Moderate-to-Severe Thyroid Eye Disease: A Phase 1/2 Randomized, Double-Masked, Placebo-Controlled Study
- Efficacy, Safety, and Tolerability of Subcutaneous Teprotumumab in Moderate-to-Severe Active Thyroid Eye Disease: A Phase 3 Randomized, Double-Masked, Placebo-Controlled Trial
Data & Insights
Has run more than one trial at 11 of 28 partner sites.
Specializations
Endocrine Ophthalmology
This investigator specializes in the management of thyroid eye disease, with particular emphasis on studying advanced therapeutic approaches for patients with moderate to severe manifestations of the condition.
- Orbital Inflammation
- Proptosis Management
- Thyroid-Related Eye Disorders
The research focus includes evaluating innovative treatments for orbital tissue inflammation and eye protrusion.
Biological Therapeutics
The investigator explores targeted biological therapies for autoimmune orbital conditions, specifically investigating novel subcutaneous administration methods for treating thyroid-associated eye disorders.
- Monoclonal Antibody Treatments
- Subcutaneous Drug Delivery
- Therapeutic Response Assessment
Their work encompasses the evaluation of innovative drug delivery systems in orbital disease management.
Clinical Measurements
The investigator focuses on developing and implementing precise clinical assessment methods for measuring orbital changes in thyroid eye disease patients.
- Proptosis Measurement
- Bilateral Eye Assessment
- Treatment Response Monitoring
Their expertise includes quantitative evaluation of orbital tissue changes and therapeutic outcomes.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.